Xcout Intel
Blue Marlin Therapeutics, Inc.
Blue Marlin Therapeutics is developing a non-viral, in vivo immune-cell engineering platform that combines targeted lipid nanoparticle delivery, genomic integration, and promoter-gated expression. The company aims to provide durable, cell-specific therapies for patients with oncology and autoimmune diseases.
Subscribe to see Blue Marlin Therapeutics, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Blue Marlin Therapeutics, Inc. at a glance
Blue Marlin Therapeutics, Inc. is a biotechnology company headquartered in United States. Its most recent funding round raised $100,000 in October 2025. Xcout tracks 9 named people at Blue Marlin Therapeutics, Inc., including Sean Stalfort (President).
Blue Marlin Therapeutics, Inc. leadership
- Sean StalfortPresident
- Sean StalfortCEO & Founder
- Joseph SennChief Development and Science Officer & Co-founder
- Oleg IartchoukHead of Research & Co-founder
- Justin PowersHead of Business Development
- Edward OakeleyExecutive Director, Bioinformatics and Data Analysis
3 more named people on record for Blue Marlin Therapeutics, Inc., with roles, board committees and tenure — see the full roster →
Blue Marlin Therapeutics, Inc. funding rounds
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| SEC Form D filing | $100,000 | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Blue Marlin Therapeutics, Inc. competitors
A few of Blue Marlin Therapeutics, Inc.'s closest competitors — see the full list of competitors and alternatives →
Walking Fish Therapeutics develops cell-based therapeutics by engineering B cells to act as protein factories for the treatment of serious diseases, including oncology, regenerative medicine, autoimmune diseases, and rare deficiency diseases. The company utilizes a proprietary B cell platform to deliver various therapeutic proteins such as replacement proteins, immune-inhibitory proteins, and engineered antibodies.
Sail Biomedicines develops a new class of RNA medicines and in vivo CAR-T cell therapies designed to reset autoimmunity and treat immune-mediated diseases. The company utilizes an integrated platform combining Endless RNA (eRNA) constructs and targeted nanoparticles to deliver protein cargos directly to specific immune cells inside the body.
Adaptin Bio is a biotechnology company developing a proprietary drug delivery platform designed to enhance the transfer of therapeutics across biological barriers into the brain and other targeted tissues. Its lead technology, the Brain Bispecific T cell Engager (BRiTE) platform, manipulates the human immune system to target diseases in oncology, central nervous system disorders, autoimmune conditions, and cardiovascular markets.
CPTx is a genetic medicines company that develops in vivo CAR-T therapies for cancer treatment. The company utilizes a proprietary single-stranded DNA (ssDNA) platform combined with lipid nanoparticle delivery systems to create scalable, non-viral genetic therapies.
ImCheck Therapeutics designs and develops next-generation immunotherapeutic antibodies focused on modulating the immune system through the butyrophilin and butyrophilin-like superfamily of checkpoint molecules. The company's pipeline targets treatments for cancer, infectious disease, and autoimmune disease.
Base Therapeutics is a biotechnology company that develops next-generation gene editing technologies, including its proprietary AccuBase base editing system and enhanced prime editing technology. The company focuses on creating therapeutic solutions for cancer and genetic diseases, alongside engineered immune cell therapies such as BASE-NK and CAR-T products. It serves patients and partners with pharmaceutical and agricultural enterprises by licensing its precision gene editing tools.
Get Blue Marlin Therapeutics, Inc.'s news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Blue Marlin Therapeutics, Inc. in Xcout Intel
- 9 named people with titles, LinkedIn and board committees
- 1 funding round with the investors in each, and who they co-invest with
- The full competitor set, tracking, exports and API access